Amphastar Pharmaceuticals, Inc.（AMPH）の財務AMPHAmphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. (AMPH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Other finished pharmaceutical products, accounting for 19.0% of total sales, equivalent to $34.65M. Other significant revenue streams include Epinephrine and Glucagon. Understanding this composition is critical for investors evaluating how AMPH navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Amphastar Pharmaceuticals, Inc. maintains a gross margin of 50.83%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 21.60%, while the net margin is 16.50%. These profitability ratios, combined with a Return on Equity (ROE) of 10.30%, provide a clear picture of how effectively AMPH converts its operational activities into shareholder value.

In the context of the broader market, AMPH competes directly with industry leaders such as BCAX and DMRA. With a market capitalization of $1.13B, it holds a significant position in the sector. When comparing efficiency, AMPH's gross margin of 50.83% stands against BCAX's N/A and DMRA's N/A. Such benchmarking helps identify whether Amphastar Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Amphastar's revenue growth has been lackluster, with only 3.2% annualized growth over the past two years. The gross margin has fluctuated, with the most recent quarter showing 50.83%, but this is down from higher levels in previous quarters. The net income for the last quarter was $30.35 million, reflecting ongoing profitability issues.